Bayer relaunches world’s No. 1 antifungal brand Canesten® in India
11 May 2022 – The Consumer Health division of Bayer announced the launch of the new and improved range of Canesten®, their anti-fungal treatment solution in India. Available in powder and cream formats, the product range offers anti-fungal properties that helps prevent and treat skin infections. An easy-to-use solution, Canesten® is a full-cycle skin infection control formulation that not only provides relief from itching but also halts the spread of infection.
Based on Bayer's original research molecule Clotrimazole, the Canesten® range brings the required relief as it treats a wide spectrum of fungal skin infections. Canesten® anti-fungal dusting powder is used in the prevention, therapy and follow-up treatment of superficial skin fungal infections and provides 5X relief vs. ordinary talcum powder from prickly heat, redness, skin irritation, itching, and fungal infection. Canesten® cream, provides relief from ringworm, jock itch, skin candidiasis, athlete's foot, erythrasma and fungal nail infection, among other fungal skin infections. Canesten® S cream is used for treatment of skin fungal infections with inflammatory lesions, while Canesten® V6 Tablets proves its effectiveness in the therapy of complicated vulvovaginal candidosis¹.
Available in 110 countries, a global market leader in anti-fungal solutions, the launch of Canesten® in India highlights Bayer’s commitment to focus on bringing science-based solutions to consumers around the world, throughout all stages of life. With solutions like Canesten®, Bayer intends to address treatment of skin fungal infections among women, which tend to get ignored. Women usually disregard the first sign of discomfort from fungal infections, continuing to bear them and using home remedies to treat them. Talcum powder is a common household remedy for sweat, prickly heat, and rash in India, which women use without any conscious consideration or judgement of whether it provides the right cure or not. The communication planned by the Consumer Health division for Canesten® aims to combat this behaviour by encouraging the use of an expert solution.
Talking about the launch, Sandeep Verma, Country Head, Bayer Consumer Heath India, said, "At Bayer, we are continuously working on our vision of making self-care accessible for all Indians. Women, especially those who lead a more active lifestyle, are prone to fungal skin infections in the hot-humid weather of India. Early symptom detection, diagnosis and treatment can provide relief,
reduce the likelihood of recurrence, and improve their quality of life. To address this concern, we've brought our best global solution to India, that’s already trusted by millions of women worldwide. We want to encourage women to stop being uncomfortable and hiding fungal skin infections, rather treat them with Canesten®, and live their lives to the fullest.”
“As we focus on strengthening our dermatology portfolio in India, we are determined to take the legacy of Bayer's original research molecule Clotrimazole to new heights and establish Canesten® as the go-to solution for skin infection in women,” he further added.
Canesten® dusting powder is available as 50g and 100g SKUs (Stock Keeping Units) while Canesten® cream is available in a 30g tube - all of which can be purchased as an OTC product across India. The other 2 SKUs, Canesten® S cream in 15gm tube and Canesten® V6 tablets can be purchased with a doctor’s prescription.
Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and ageing global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
Find more information visit www.bayer.in
Business Partner Communications – Pharma & Consumer Health
Contact : +91 9833 841760
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.